GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Accounts Receivable

Mesoblast (Mesoblast) Accounts Receivable : $1.80 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Mesoblast's accounts receivables for the quarter that ended in Dec. 2023 was $1.80 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Mesoblast's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.08.


Mesoblast Accounts Receivable Historical Data

The historical data trend for Mesoblast's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Accounts Receivable Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.74 0.68 2.00 2.22 2.28

Mesoblast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 2.28 - 1.80 -

Mesoblast Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Mesoblast Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Mesoblast's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.804/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Mesoblast's accounts receivable are only considered to be worth 75% of book value:

Mesoblast's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(77.144+0.75 * 1.804+0.5 * 0-161.554
-0-0)/1014.8
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Mesoblast Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Mesoblast's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Mesoblast (Mesoblast) Headlines

From GuruFocus

Mesoblast Financial Results and Corporate Update Webcast

By sperokesalga sperokesalga 05-24-2023

Jane Bell Joins Mesoblast Board

By PurpleRose PurpleRose 08-18-2022

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

By sperokesalga sperokesalga 03-22-2023

Appendix 4C Quarterly Activity Report

By PurpleRose PurpleRose 07-29-2022

Appendix 4C Quarterly Activity Report

By Stock market mentor Stock market mentor 01-31-2023